BCCA Protocol Summary for Recurrent/Metastatic Salivary Gland cancers of the Head and Neck with Tamoxifen

Protocol Code: HNSAVTAM

Tumour Group: Head and Neck

Contact Physician: Dr. Cheryl Ho

ELIGIBILITY:
- ER positive or negative status
- Recurrent malignancy for whom resection, radiotherapy or chemotherapy are no longer treatment options
- Current evidence based on case studies

TESTS:
- Histologically confirmed recurrence of a salivary gland carcinoma

TREATMENT:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tamoxifen</td>
<td>20 mg PO once daily</td>
<td>PO</td>
</tr>
</tbody>
</table>

- DISCONTINUE drug for severe side effects OR obvious progression of disease

PRECAUTIONS:
1. **Women:** hot flushes, vaginitis.
2. **Men:** decrease in libido, hot flushes.
3. **Thromboembolism:** Tamoxifen is associated with an increased risk of thromboembolism that is comparable to estrogen replacement therapy.

Contact Dr. Cheryl Ho or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date Activated: 1 Feb 2012

Date(s) Revised

REFERENCE